Connect with us

Health

Single dose of 'magic mushrooms' provides 5 years of depression relief, researchers find

Published

on

Single dose of 'magic mushrooms' provides 5 years of depression relief, researchers find

NEWYou can now listen to Fox News articles!

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, followed up with patients who had been diagnosed with clinical depression — also known as major depressive disorder (MDD) — and had participated in a previous psilocybin treatment study in 2020.

“Most people who participated in our trial reported improvements in depression symptom intensity or in the ways in which they experienced depression in their life, lasting up to five years after the trial,” study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Fox News Digital.

PSYCHEDELICS AS POTENTIAL MENTAL HEALTH TREATMENT ARE EXPLORED BY TRUMP ADMINISTRATION

Advertisement

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that the outcome speaks to the “exciting” potential of psilocybin and other psychedelic-based treatments in treating MDD and other mental health conditions.

“The results of the study are certainly very encouraging,” said Drysdale, who was not involved in the study.

A worker holds dried psychedelic mushrooms. The results of the new study are “certainly very encouraging,” said one pharmaceutical company executive.  (James MacDonald/Bloomberg via Getty Images)

Earlier studies pointed toward the possibility of psilocybin as a potential antidepressant, prompting researchers to conduct the first-ever randomized clinical trial.

The initial 2020 trial, published in JAMA Psychiatry, included 24 patients with major depressive disorder. Half received psilocybin at the beginning of the trial, and the other half received the treatment eight weeks later. 

Advertisement

Each patient also underwent 11 hours of psychotherapy.

WHAT IS KETAMINE THERAPY? MORMON REALITY STARS TOUT CONTROVERSIAL TREATMENT

One month after treatment, 17 patients reported experiencing symptom relief. Fourteen of those reported full remission from depression, according to the published study.

“The effectiveness of psilocybin therapy after a single or only a few administrations represents another substantial advantage over commonly used antidepressants that require daily administration,” the researchers wrote.

Patients appeared to respond much faster to psychedelics than to traditional antidepressants, the researchers stated. (James MacDonald/Bloomberg via Getty Images)

Advertisement

The new study aimed to explore the longer-term effects of this treatment on 21 of the original trial participants.

Sixty-seven percent reported being in remission from depression five years after treatment, and they also had less anxiety and easier daily functioning.

“The study doesn’t account for naturalistic changes that could have affected their depression in the five years since the main trial.”

For those whose depression came back, many still reported lasting benefits in their attitudes, perspectives and ability to pursue things that were meaningful to them, Davis told Fox News Digital.

“Certainly, more controlled and rigorous study is required, but at least anecdotally, these findings are very interesting, and I am cautiously optimistic about the potential for extended efficacy provided by these types of treatments,” Drysdale added.

Advertisement

Sixty-seven percent of participants reported being in remission from depression five years after treatment, and they also had less anxiety and easier daily functioning. (JASON CONNOLLY/AFP via Getty Images)

Other factors may have also played a role in the participants’ long-term mental health benefits, such as psychotherapy sessions or other antidepressants, experts agreed.

“The study doesn’t account for naturalistic changes that could have affected their depression in the five years since the main trial, and the sample is not representative of the population of people suffering with depression,” Davis told Fox News Digital.

PARKINSON’S PATIENTS WHO TAKE ‘MAGIC MUSHROOMS’ SEE KEY BENEFITS, STUDY FINDS

Psilocybin has also been explored as a potential treatment for post-partum depression (PPD), which affects as many as one in seven new mothers.

Advertisement

A 2022 study outlined the potential role of psychedelics in PPD cases, finding that psilocybin has been shown to catalyze a sense of “reconnection” in new mothers.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“This effect in PPD, by fostering a sense of ‘reconnection’ for the mother, may allow for improved mood and maternal sensitivity toward the infant, which can positively impact maternal role gratification and the mother-infant relationship,” the researchers stated.

In February, Cleveland Clinic reported on an upcoming study that explores single-dosing psilocybin as a way to treat PPD.

Psilocybin has been explored as a potential treatment for post-partum depression (PPD), which affects as many as one in seven new mothers. (iStock)

Advertisement

The trial, now in its second phase, focuses on RE104, a proprietary drug similar to psilocybin. 

Study participants will undergo multiple physical and mental health tests.

Potential risks and limitations

Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, has emphasized the importance of administering psychedelics in a safe setting when treating mental health conditions.

For more Health articles, visit www.foxnews.com/health

“Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia,” Moss previously told Fox News Digital. 

Advertisement

Experts recommend that therapeutic use of psychedelics should be carefully managed by medical experts.

“Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. 

Other factors may have also played a role in the participants’ long-term mental health benefits, noted an expert (not pictured), such as psychotherapy sessions or other antidepressants. (iStock)

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News’ senior medical analyst, previously interviewed two of the country’s top researchers on psychedelics: Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone.

Advertisement

“They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses,” Siegel told Fox News Digital at the time.

“Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts,” Siegel added.

Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reporting.

Advertisement

Health

Experts Call It 2026’s Best Diet— ‘The Results Are Often Stunning’

Published

on

Experts Call It 2026’s Best Diet— ‘The Results Are Often Stunning’


Advertisement


Best Diet of 2026 Doubles Weight Loss, Burns Belly Fat Fast| Woman’s World




















Advertisement











Advertisement




Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Deadly ‘superbug’ is spreading across US as drug resistance grows, researchers warn

Published

on

Deadly ‘superbug’ is spreading across US as drug resistance grows, researchers warn

NEWYou can now listen to Fox News articles!

A deadly, drug-resistant fungus already spreading rapidly through U.S. hospitals is becoming even more threatening worldwide, though there may be hope for new treatments, according to a new scientific review.

Candida auris (C. auris), often described as a “superbug fungus,” is spreading globally and increasingly resisting human immune systems, Hackensack Meridian Center for Discovery and Innovation (CDI) researchers said in a review published in early December.

The findings reinforce prior CDC warnings that have labeled C. auris an “urgent antimicrobial threat” — the first fungal pathogen to receive that designation — as U.S. cases have surged, particularly in hospitals and long-term care centers.

DANGEROUS SPIKE IN SUPERBUG INFECTIONS SURGES ACROSS US AS EXPERTS SHARE CAUTIONS

Advertisement

Approximately 7,000 cases were identified across dozens of U.S. states in 2025, according to the CDC, and it has reportedly been identified in at least 60 countries.

Candida auris is a drug-resistant fungus spreading in hospitals worldwide. (Nicolas Armer/Picture Alliance via Getty Images)

The review, published in Microbiology and Molecular Biology Reviews, helps explain why the pathogen is so difficult to contain and warns that outdated diagnostics and limited treatments lag behind. It was conducted by Dr. Neeraj Chauhan of the Hackensack Meridian CDI in New Jersey, Dr. Anuradha Chowdhary of the University of Delhi’s Medical Mycology Unit and Dr. Michail Lionakis, chief of the clinical mycology program at the National Institutes of Health.

Their findings stress the need to develop “novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients,” the researchers said in a statement.

GROWING ANTIBIOTIC CRISIS COULD TURN BACTERIAL INFECTIONS DEADLY, EXPERTS WARN

Advertisement

“In addition, future efforts should focus on raising awareness about fungal disease through developing better surveillance mechanisms, especially in resource-poor countries,” they added. “All these developments should help improve the outcomes and prognosis of patients afflicted by opportunistic fungal infections.”

Candida auris can survive on skin and hospital surfaces, allowing it to spread easily. (iStock)

First identified in 2009 from a patient’s ear sample in Japan, C. auris has since spread to dozens of countries, including the U.S., where outbreaks have forced some hospital intensive care units to shut down, according to the researchers.

The fungus poses the greatest risk to people who are already critically ill, particularly those on ventilators or with weakened immune systems. Once infected, about half of patients may die, according to some estimates.

FLU BY STATE: WHERE THIS SEASON’S HIGHLY CONTAGIOUS VARIANT IS SPREADING THE MOST

Advertisement

Unlike many other fungi, C. auris can survive on human skin and cling to hospital surfaces and medical equipment, allowing it to spread easily in healthcare settings.

“It is resistant to multiple antifungal drugs, and it tends to spread in hospital settings, including on equipment being used on immunocompromised and semi-immunocompromised patients, such as ventilators and catheters,” Dr. Marc Siegel, Fox News senior medical analyst and clinical professor of medicine at NYU Langone, previously told Fox News Digital.

Scientists say the unique cell wall structure of C. auris makes it harder to kill. (iStock)

It is also frequently misdiagnosed, delaying treatment and infection control measures.

Advertisement

“Unfortunately, symptoms such as fever, chills and aches may be ubiquitous, and it can be mistaken for other infections,” Siegel said.

In September, he said intense research was ongoing to develop new treatments.

Only four major classes of antifungal drugs are currently available, and C. auris has already shown resistance to many of them. While three new antifungal drugs have been approved or are in late-stage trials, researchers warn that drug development has struggled to keep pace with the fungus’s evolution.

CLICK HERE FOR MORE LIFESTYLE STORIES

Despite the sobering findings, there is still room for cautious optimism.

Advertisement

The fungus can cling to skin and hospital surfaces, aiding its spread. (iStock)

In separate research published in December, scientists at the University of Exeter in England discovered a potential weakness in C. auris while studying the fungus in a living-host model. 

The team found that, during infection, the fungus activates specific genes to scavenge iron, a nutrient it needs to survive, according to their paper, published in the Nature portfolio journal Communications Biology in December.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Because iron is essential for the pathogen, researchers believe drugs that block this process could eventually stop infections or even allow existing medications to be repurposed.

Advertisement

“We think our research may have revealed an Achilles’ heel in this lethal pathogen during active infection,” Dr. Hugh Gifford, a clinical lecturer at the University of Exeter and co-author of the study, said in a statement.

New research is underway to develop better treatments and diagnostics for C. auris. (iStock)

As researchers race to better understand the fungus, officials warn that strict infection control, rapid detection and continued investment in new treatments remain critical.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Health experts emphasize that C. auris is not a threat to healthy people.

Advertisement

Fox News Digital has reached out to the CDI researchers and additional experts for comment.

Fox News Digital’s Angelica Stabile contributed reporting.

Advertisement
Continue Reading

Health

Record-breaking flu numbers reported in New York state, sparking warnings from officials

Published

on

Record-breaking flu numbers reported in New York state, sparking warnings from officials

NEWYou can now listen to Fox News articles!

The New York State Department of Health reported a record surge in influenza activity, with 71,123 positive flu cases recorded statewide during the week ending December 20.

Advertisement

Health officials said the figure represents the highest number of flu cases ever reported in a single week since influenza became a reportable disease in New York in 2004.

State health data show the weekly total reflects a 38% increase from the previous reporting period, signaling a rapidly intensifying flu season.

There have been 189,312 reported positive flu cases so far this season, while influenza-related hospitalizations rose 63% in the most recent week.

FLU BY STATE: WHERE THIS SEASON’S HIGHLY CONTAGIOUS VARIANT IS SPREADING THE MOST

New York reported the highest weekly total of cases ever recorded since influenza became reportable in 2004. (iStock)

Advertisement

“We are seeing the highest number of flu cases ever recorded in a single week in New York state,” Health Commissioner Dr. James McDonald said in a press release.

There have been 189,312 reported flu cases so far this season, with influenza-related hospitalizations increasing 63% in the most recent week. (iStock)

Earlier this month, the department declared influenza prevalent statewide, a designation that requires unvaccinated health care workers to wear masks in patient care settings.

SURGE IN WHOOPING COUGH CASES IN SOUTHERN STATE PROMPTS HEALTH ALERTS

Health officials continue to emphasize that vaccination remains the most effective way to prevent severe illness and hospitalization from influenza.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

New Yorkers who have not yet received a seasonal flu shot are still encouraged to do so, with experts saying vaccination can offer protection even later in the season.

Health officials continue to urge New Yorkers to take preventive steps, including vaccination and staying home when sick, to limit further spread. (iStock)

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

To help limit further spread, the department advises individuals experiencing flu-like symptoms — including fever, cough, sore throat, or body aches — to stay home. State health officials also recommend frequent handwashing, using hand sanitizer, and avoiding close contact with sick individuals.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

For those who become ill, officials say antiviral medications are available and are most effective when started within 48 hours of symptom onset.

Health officials also added that people at higher risk for complications should contact a health care provider promptly for evaluation and possible treatment.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The department noted that flu activity typically peaks in January, meaning case counts could continue to climb in the weeks ahead.

Advertisement

Continue Reading
Advertisement

Trending